126 related articles for article (PubMed ID: 24966790)
1. Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol.
Dudkiewicz-Wilczyńska J; Grabowska A; Książek I; Sitarz K; Suchocki P; Anuszewska E
Contemp Oncol (Pozn); 2014; 18(2):90-4. PubMed ID: 24966790
[TBL] [Abstract][Full Text] [Related]
2. The activity of Selol in multidrug-resistant and sensitive human leukemia cells.
Suchocki P; Misiewicz I; Skupinska K; Waclawek K; Fijalek Z; Kasprzycka-Guttman T
Oncol Rep; 2007 Oct; 18(4):893-9. PubMed ID: 17786352
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.
Perez-Soler R; Ling YH; Zou Y; Priebe W
Cancer Chemother Pharmacol; 1994; 34(2):109-18. PubMed ID: 8194162
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of glutathione-related genes, enzyme activities and transport proteins in human cervical cancer cells treated with doxorubicin.
Drozd E; Krzysztoń-Russjan J; Marczewska J; Drozd J; Bubko I; Bielak M; Lubelska K; Wiktorska K; Chilmonczyk Z; Anuszewska E; Gruber-Bzura B
Biomed Pharmacother; 2016 Oct; 83():397-406. PubMed ID: 27424321
[TBL] [Abstract][Full Text] [Related]
5. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells.
Fritzer M; Szekeres T; Szüts V; Jarayam HN; Goldenberg H
Biochem Pharmacol; 1996 Feb; 51(4):489-93. PubMed ID: 8619895
[TBL] [Abstract][Full Text] [Related]
7. Artemisinin modulating effect on human breast cancer cell lines with different sensitivity to cytostatics.
Chekhun VF; Lukianova NY; Borikun TV; Zadvorny TV; Mokhir A
Exp Oncol; 2017 Mar; 39(1):25-29. PubMed ID: 28361857
[TBL] [Abstract][Full Text] [Related]
8. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells.
Gatouillat G; Magid AA; Bertin E; El btaouri H; Morjani H; Lavaud C; Madoulet C
Phytomedicine; 2015 Dec; 22(13):1186-94. PubMed ID: 26598918
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance.
Solary E; Ling YH; Perez-Soler R; Priebe W; Pommier Y
Int J Cancer; 1994 Jul; 58(1):85-94. PubMed ID: 8014019
[TBL] [Abstract][Full Text] [Related]
10. Selol nanocapsules with a poly(methyl vinyl ether-co-maleic anhydride) shell conjugated to doxorubicin for combinatorial chemotherapy against murine breast adenocarcinoma in vivo.
Ganassin R; Horst FH; Camargo NS; Chaves SB; Morais PC; Mosiniewicz-Szablewska E; Suchocki P; Figueiró Longo JP; Azevedo RB; Muehlmann LA
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1046-1052. PubMed ID: 29842818
[TBL] [Abstract][Full Text] [Related]
11. Codelivery of Doxorubicin and Verapamil for Treating Multidrug Resistant Cancer Cells.
Williams JB; Buchanan CM; Pitt WG
Pharm Nanotechnol; 2018; 6(2):116-123. PubMed ID: 30207210
[TBL] [Abstract][Full Text] [Related]
12. Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro.
Ganassin R; Merker C; Rodrigues MC; Guimarães NF; Sodré CSC; Ferreira QDS; da Silva SW; Ombredane AS; Joanitti GA; Py-Daniel KR; Zhang J; Jiang CS; de Morais PC; Mosiniewicz-Szablewska E; Suchocki P; Longo JPF; Meijer J; Estrela-Lopis I; de Azevedo RB; Muehlmann LA
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2002-2012. PubMed ID: 29179603
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
14. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells.
Minko T; Batrakova EV; Li S; Li Y; Pakunlu RI; Alakhov VY; Kabanov AV
J Control Release; 2005 Jul; 105(3):269-78. PubMed ID: 15939500
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
16. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells.
Ling YH; Zou Y; Priebe W; Perez-Soler R
Int J Cancer; 1995 May; 61(3):402-8. PubMed ID: 7729954
[TBL] [Abstract][Full Text] [Related]
17. Intracellular glutathione level and efflux in human melanoma and cervical cancer cells differing in doxorubicin resistance.
Drozd E; Gruber B; Marczewska J; Drozd J; Anuszewska E
Postepy Hig Med Dosw (Online); 2016 Apr; 70():319-28. PubMed ID: 27117108
[TBL] [Abstract][Full Text] [Related]
18. Effects of high-intensity interval training on the expression of microRNA-499 and pro- and anti-apoptotic genes in doxorubicin-cardiotoxicity in rats.
Alihemmati A; Ebadi F; Moghadaszadeh M; Asadi M; Zare P; Badalzadeh R
J Electrocardiol; 2019; 55():9-15. PubMed ID: 31048226
[TBL] [Abstract][Full Text] [Related]
19. Effect of BN Nanoparticles Loaded with Doxorubicin on Tumor Cells with Multiple Drug Resistance.
Zhitnyak IY; Bychkov IN; Sukhorukova IV; Kovalskii AM; Firestein KL; Golberg D; Gloushankova NA; Shtansky DV
ACS Appl Mater Interfaces; 2017 Sep; 9(38):32498-32508. PubMed ID: 28857548
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
